Logo

TLSA

Tiziana Life Sciences Ltd

TLSA

Tiziana Life Sciences Ltd • NASDAQ
$1.80 ▲ 0.56% (+0.01)
Market Cap $100.32 M
52w High $2.60
52w Low $0.63
Dividend Yield 0%
P/E -15
Volume 79.99K
Outstanding Shares 55.73M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $0 $9.132M ▼ $-7.209M ▲ 0% $-0.13 ▲ $-8.699M ▲
Q2-2024 $0 $12.76M ▲ $-9.308M ▼ 0% $-0.18 $-15.834M ▼
Q4-2023 $0 $6.192M ▼ $-9.074M ▼ 0% $-0.18 ▼ $-8.579M ▼
Q2-2023 $0 $11.792M ▲ $-8.617M ▲ 0% $-0.16 ▲ $-8.557M ▲
Q4-2022 $0 $9.994M $-10.884M 0% $-0.22 $-10.831M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $3.724M ▲ $11.284M ▲ $7.348M ▼ $3.936M ▲
Q2-2024 $1.13M ▼ $10.964M ▼ $9.109M ▲ $1.855M ▼
Q4-2023 $1.183M ▼ $12.184M ▼ $6.648M ▲ $5.536M ▼
Q2-2023 $6.597M ▼ $17.418M ▼ $4.123M ▼ $13.295M ▼
Q4-2022 $18.122M $26.477M $6.906M $19.571M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-5.761M ▼ $-1.539M ▼ $-45.548K ▼ $3.655M ▲ $2.073M ▲ $-1.543M ▼
Q2-2024 $-3.677M ▲ $316.004K ▲ $-11.06K ▲ $-54.51K ▼ $-41.87K ▲ $304.943K ▲
Q4-2023 $-7.181M ▼ $-3.408M ▲ $-790.562K ▼ $60.934K ▲ $-4.284M ▲ $-3.408M ▲
Q2-2023 $-6.803M ▲ $-8.993M ▼ $-200.517K ▲ $-29.209K ▲ $-9.098M ▼ $-8.993M ▼
Q4-2022 $-8.873M $-6.279M $-418.195K $-44.835K $-6.865M $-6.279M

Five-Year Company Overview

Income Statement

Income Statement Tiziana is still a pure research‑stage biotech with no product sales yet, so its income statement is all costs and no revenue. The company has been running steady losses for several years, which is typical for a small clinical‑stage biotech. The size of the loss appears modest and has been slowly improving over time, suggesting tighter cost control or a more focused R&D spend. Still, the business is entirely dependent on external funding rather than internally generated profits at this stage.

Balance Sheet

Balance Sheet The balance sheet is very small and lean. Total assets and cash have trended down over the last several years, reflecting ongoing use of resources to fund research. There is essentially no financial debt, which simplifies the capital structure but also means the company mainly relies on equity and possibly other non‑debt sources to finance itself. Shareholders’ equity has been shrinking as losses accumulate, highlighting limited financial cushion and the importance of future capital raises or partnerships.

Cash Flow

Cash Flow Cash flows are negative from operations, in line with a company spending on clinical trials but not yet selling products. Free cash flow has also been consistently negative, although capital spending on physical assets is minimal; most cash goes straight into R&D and overhead. Recent cash outflows look somewhat smaller than in earlier years, which may reflect tighter spending or a more targeted pipeline. Overall, the company’s ability to keep funding its programs depends on raising new cash rather than generating it internally.

Competitive Edge

Competitive Edge Tiziana’s competitive strength comes from a very focused niche: neuro‑immunology using a fully human anti‑CD3 antibody (foralumab) and novel intranasal, oral, and inhaled delivery routes. Being early and differentiated in nasal antibody delivery for neurodegenerative diseases gives it a clear scientific angle and some first‑mover advantages. A broad patent estate around foralumab, delivery methods, and combinations helps protect this position. However, the company is small, has no approved products, and operates in a field where large pharma and other biotechs are also active, so it faces intense competition for patients, trial sites, and eventual market share if its drugs succeed.

Innovation and R&D

Innovation and R&D Innovation and R&D are the core of the company. Foralumab is a versatile lead asset being tested or prepared for testing in multiple serious conditions like progressive multiple sclerosis, Alzheimer’s disease, and ALS, with an emphasis on modulating the immune system via the nose to reach the brain more effectively and safely. Additional programs, such as an anti‑IL‑6 receptor antibody and an oncology drug (milciclib), add depth and show that the platform extends beyond a single asset. The pipeline is rich in scientific potential but also carries classic biotech risks: trial delays, uncertain clinical outcomes, regulatory hurdles, and the need for substantial ongoing funding to advance multiple programs in parallel.

Summary

Tiziana Life Sciences is an early‑stage, high‑risk, high‑uncertainty biotech built around a distinctive neuro‑immunology platform and a novel drug delivery approach, but it remains pre‑revenue and loss‑making. Financially, it has a small and shrinking asset base, no debt, negative cash flow, and relies on external capital to fund research. Strategically, it holds a differentiated scientific position with strong patent protection and a lead drug that could be applied across several major neurological and inflammatory diseases. The company’s future will likely be shaped by the success or failure of its mid‑stage clinical trials, its ability to secure partnerships or funding, and its capacity to translate promising science into approved therapies and commercial returns.

NEWS

November 25, 2025 · 8:30 AM UTC

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Read more

November 13, 2025 · 8:30 AM UTC

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Read more

October 29, 2025 · 7:00 AM UTC

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Read more

September 30, 2025 · 8:30 AM UTC

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Read more

September 24, 2025 · 8:30 AM UTC

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Read more